References
- Fiechtner JJ, Montroy T. Treatment of moderately to severely active systemic lupus erythematosus with adrenocorticotropic hormone: a single-site, open-label trial. Lupus 2014;23:905-12
- Prescribing information of H.P. Acthar Gel. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022432s000lbl.pdf. [Last accessed 30 July 2015]
- H.P. Acthar® Gel (repository corticotropin injection) [prescribing information]. Mallinckrodt ARD, Inc. https://www.actharrheumatology.com/systemic-lupus-erythematosus/overview. [Last accessed 12 May 2016]
- Questcor Pharmaceuticals, Inc. Prescribing Information: Acthar. http://acthar.com/pdf/Acthar-PI.pdf. [Last accessed 27 March 2015]
- Lateef A, Petri M. Unmet medical needs in systemic lupus erythematosus. Arthritis Res Ther 2012;14(Suppl 4):S4
- Doria A, Gatto M, Iaccarino L, et al. Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight. Lupus 2015;24:507-15
- Doria A, Gatto M, Zen M, et al. Optimizing outcome in SLE: treating-to-target and definition of treatment goals. Autoimmun Rev 2014;13:770-7
- Emery P. Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Rheumatology (Oxford) 2012;51(Suppl 5):v22-30
- Pavelka K, Kavanaugh AF, Rubbert-Roth A, et al. Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2012;51(Suppl 5):v12-21
- Rubbert-Roth A. Assessing the safety of biologic agents in patients with rheumatoid arthritis. Rheumatology (Oxford) 2012;51(Suppl 5):v38-47
- CDC. Rheumatoid arthritis. http://www.cdc.gov/arthritis/basics/rheumatoid.htm. [Last accessed 27 February 2015]
- Salaffi F, Carotti M, Gasparini S, et al. The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people. Health Qual Life Outcomes 2009;7:25
- Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:15-25
- Greenapple R. Trends in biologic therapies for rheumatoid arthritis: results from a survey of payers and providers. Am Health Drug Benefits 2012;5:83-92
- Arthritis Foundation. Rheumatoid arthritis treatment. http://www.arthritis.org/about-arthritis/types/rheumatoid-arthritis/treatment.php. [Last accessed 14 July 2015]
- Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum 1999;42:1785-96
- Garris C, Jhingran P, Bass D, et al. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan. J Med Econ 2013;16:667-77
- Garris C, Shah M, Farrelly E. The prevalence and burden of systemic lupus erythematosus in a medicare population: retrospective analysis of medicare claims. Cost Eff Resour Alloc 2015;13:9
- Ruperto N, Hanrahan LM, Alarcon GS, et al. International consensus for a definition of disease flare in lupus. Lupus 2011;20:453-62
- Balluz L, Philen R, Ortega L, et al. Investigation of systemic lupus erythematosus in Nogales, Arizona. Am J Epidemiol 2001;154:1029-36
- Naleway AL, Davis ME, Greenlee RT, et al. Epidemiology of systemic lupus erythematosus in rural Wisconsin. Lupus 2005;14:862-6
- Uramoto KM, Michet CJ Jr, Thumboo J, et al. Trends in the incidence and mortality of systemic lupus erythematosus, 1950–1992. Arthritis Rheum 1999;42:46-50
- Furie R, Mitrane M, Zhao E, et al. Efficacy and tolerability of repository corticotropin injection in patients with persistently active SLE: results of a phase 4, randomised, controlled pilot study. Lupus Sci Med 2016;3:e000180
- Myung G, Nelson WW, McMahon MA. Effects of repository corticotropin injection on medication use in patients with rheumatologic conditions: a claims data study. J Pharm Technol 2017;33:151-155
- Knight T, Bond TC, Popelar B, et al. Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab. Clinicoecon Outcomes Res 2017;9:271-9
- Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
- Kan H, Guerin A, Kaminsky MS, et al. A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus. J Med Econ 2013;16:793-800